Sugarbaker Paul H, Stuart O Anthony, Yoo Dal
Washington Cancer Institute, Washington, DC 20010, USA.
J Oncol Pharm Pract. 2005 Sep;11(3):111-9. doi: 10.1191/1078155205jp157oa.
A prominent part of treatment failure of gastrointestinal and gynecologic malignancy is dissemination to peritoneal surfaces. This has been associated with a limited survival and no reliable treatment strategies.
A review of the natural history of carcinomatosis was performed and a rationale for intraperitoneal chemotherapy was sought. The pharmacology of chemotherapy administration into the peritoneal cavity was reviewed.
The technology of perioperative intraperitoneal chemotherapy requires the administration of drugs along with moderate hyperthermia in the operating room as a planned part of the surgical procedure. The solution in which the chemotherapy is diluted has an effect upon the drug clearance from the peritoneal cavity. Also, the volume of the carrier solution affects the exposure of cancer nodules on peritoneal surfaces .
New combinations of intraperitoneal chemotherapy administration when combined with optimal surgical technology for maximal chemotherapy effects should result in benefit to patients with peritoneal surface dissemination of gastrointestinal and gynecologic malignancy.
胃肠道和妇科恶性肿瘤治疗失败的一个突出原因是癌细胞扩散至腹膜表面。这与生存期有限以及缺乏可靠的治疗策略有关。
对癌性腹膜炎的自然病史进行了回顾,并探寻了腹腔内化疗的理论依据。对腹腔内化疗给药的药理学进行了综述。
围手术期腹腔内化疗技术要求在手术室中将药物与适度热疗一起给药,作为手术程序的一个计划部分。化疗药物稀释所用的溶液对药物从腹腔内清除有影响。此外,载体溶液的体积会影响腹膜表面癌结节的暴露情况。
腹腔内化疗给药的新组合与实现最大化疗效果的最佳手术技术相结合,应该会使胃肠道和妇科恶性肿瘤腹膜表面扩散的患者受益。